SecSonar.com

Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Madrigal Pharmaceuticals, Inc. (MDGL) is a Biotechnology company based in US with a market capitalization of $11.5B. Free cash flow was negative at -$190M. This page tracks MDGL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 528 employees · IPO Feb 6, 2007

Valuation

Valuation & price

$523.69 · as of May 17, 2026 · -13.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

19.10

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$603$446$289Jul 25Dec 25Jul 26Jul 7, 25$289.17Jul 9, 25$308.59Jul 11, 25$315.46Jul 15, 25$311.14Jul 17, 25$348.73Jul 21, 25$330.94Jul 23, 25$306.76Jul 25, 25$298.40Jul 29, 25$294.40Jul 31, 25$302.51Aug 4, 25$312.11Aug 6, 25$338.11Aug 11, 25$349.50Aug 13, 25$373.46Aug 15, 25$369.84Aug 19, 25$379.55Aug 21, 25$407.09Aug 25, 25$412.23Aug 27, 25$425.06Aug 29, 25$437.85Sep 3, 25$435.27Sep 5, 25$432.89Sep 9, 25$448.73Sep 11, 25$439.45Sep 16, 25$427.05Sep 18, 25$440.75Sep 22, 25$440.07Sep 24, 25$426.84Sep 26, 25$424.23Sep 30, 25$458.66Oct 2, 25$449.64Oct 6, 25$442.31Oct 8, 25$436.95Oct 10, 25$429.60Oct 14, 25$437.10Oct 16, 25$442.13Oct 21, 25$430.00Oct 23, 25$423.87Oct 27, 25$435.78Oct 29, 25$421.60Oct 31, 25$418.90Nov 4, 25$444.64Nov 6, 25$488.58Nov 10, 25$495.88Nov 12, 25$528.94Nov 14, 25$529.21Nov 18, 25$558.99Nov 20, 25$542.12Nov 25, 25$592.04Nov 28, 25$596.98Dec 2, 25$573.15Dec 4, 25$586.21Dec 8, 25$568.57Dec 10, 25$552.47Dec 12, 25$571.44Dec 16, 25$554.57Dec 18, 25$544.41Dec 22, 25$602.83Dec 24, 25$602.82Dec 29, 25$589.47Jan 2, 26$593.87Jan 6, 26$558.01Jan 8, 26$556.22Jan 12, 26$510.53Jan 14, 26$505.23Jan 16, 26$501.68Jan 21, 26$496.97Jan 23, 26$480.45Jan 27, 26$500.39Jan 29, 26$494.69Feb 2, 26$489.73Feb 4, 26$478.61Feb 9, 26$488.26Feb 11, 26$481.00Feb 13, 26$464.71Feb 18, 26$491.49Feb 20, 26$435.01Feb 24, 26$440.00Feb 26, 26$445.85Mar 2, 26$435.62Mar 4, 26$434.80Mar 6, 26$432.83Mar 10, 26$432.78Mar 12, 26$438.73Mar 17, 26$443.18Mar 19, 26$454.22Mar 23, 26$447.72Mar 25, 26$461.93Mar 27, 26$510.68Mar 31, 26$523.47Apr 2, 26$546.89Apr 7, 26$511.89Apr 9, 26$524.30Apr 13, 26$525.67Apr 15, 26$518.58Apr 17, 26$532.02Apr 22, 26$529.14Apr 24, 26$512.39Apr 28, 26$516.69Apr 30, 26$517.39May 4, 26$518.66May 6, 26$539.73May 8, 26$510.04May 12, 26$510.26May 14, 26$539.89May 18, 26$522.23May 20, 26$513.47May 22, 26$517.26May 28, 26$515.96Jun 1, 26$481.23Jun 3, 26$488.15Jun 5, 26$486.98Jun 9, 26$476.89Jun 11, 26$474.28Jun 15, 26$499.76Jun 17, 26$499.86Jun 22, 26$512.88Jun 24, 26$509.76Jun 26, 26$512.65Jul 2, 26$528.10
$287.5252-week range$602.83
Loading valuation history…

Fundamentals

Key fundamentals

$11.5B

Market cap

—

Revenue growth (YoY)

94.1%

Gross margin

-$190M

Free cash flow (USD)

-$629.2M

Net debt

Net cash position

5.5%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$180.1MFY 2025$958.4M
$0$958.4M

Free cash flow by year

2016 → 2025

FY 2016$-17.6MFY 2017$-22.4MFY 2018$-25.5MFY 2019$-41.8MFY 2020$-157.9MFY 2021$-184.1MFY 2022$-225.1MFY 2023$-325.7MFY 2024$-457.0MFY 2025$-190.0M
-$17.6M-$190M

Gross margin by year

2024 → 2025

FY 202496.5%FY 202594.1%
96.5%94.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventStock Plan AdoptionJun 17, 2026Filing
  • Insider sellInsider Sell $517K · 10b5-1 PlanSoergel David · Chief Medical Officer · $516.6KJun 1, 2026Filing
  • Insider sellInsider Sell $2.9M · 10b5-1 PlanLevy Richard S · Director · $2.9MMay 22, 2026Filing
  • Insider sellInsider Sell $435KSoergel David · Chief Medical Officer · $435.4KMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventBoard ReclassificationApr 28, 2026Filing

Questions

Frequently asked questions

What is Madrigal Pharmaceuticals, Inc.'s market cap?

Madrigal Pharmaceuticals, Inc. (MDGL) has a market capitalization of $11.5B.

What is MDGL's P/E ratio?

A meaningful P/E ratio is not available for MDGL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MDGL's price-to-book (P/B) ratio?

MDGL trades at 19.10 times book value per share.

Are insiders buying MDGL stock?

SEC Form 4 filings show no open-market insider buys at Madrigal Pharmaceuticals, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

AXSM

Axsome Therapeutics, Inc.

$12B

ARWR

Arrowhead Pharmaceuticals, Inc.

$10.9B

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

EXEL

Exelixis, Inc.

$12.9B

BBIO

BridgeBio Pharma, Inc.

$13.2B

CYTK

Cytokinetics, Incorporated

$9.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.